Skip to main content

Landos Biopharma, Inc. (LABP)

NASDAQ: LABP · IEX Real-Time Price · USD
15.54 0.27 (1.77%)
Sep 17, 2021 4:00 PM EDT - Market closed
Market Cap608.58M
Revenue (ttm)18.00M
Net Income (ttm)n/a
Shares Out40.12M
EPS (ttm)-1.19
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume204,923
Open15.10
Previous Close15.27
Day's Range14.65 - 15.55
52-Week Range8.82 - 16.99
Betan/a
Analystsn/a
Price Target25.50 (+64.1%)
Est. Earnings DateOct 28, 2021

About LABP

Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate in development is BT-11, an oral lanthionine synthetase C-like protein 2 (LANCL2) agonist for the treatment of ulcerative colitis (UC), Crohn's disease (CD), and inflammatory bowel diseases. The company also develops NX-13, a gut-restricted oral therapeutic that targets NOD-like receptor X1, a mitochondria-associated receptor associated with the modulation of inflammatory ...

IndustryBiotechnology
IPO DateFeb 4, 2021
Employees33
Stock ExchangeNASDAQ
Ticker SymbolLABP
Full Company Profile

Financial Performance

Financial Statements

News

Landos Biopharma to Participate in Two Upcoming Investor Conferences in September

BLACKSBURG, Va., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to develop novel or...

2 weeks ago - GlobeNewsWire

Landos Biopharma Announces Research Collaboration into the NLRX1 Pathway in Multiple Sclerosis with Johns Hopkins Uni...

BLACKSBURG, Va., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to develop novel ora...

3 weeks ago - GlobeNewsWire

Landos Biopharma to Participate in Upcoming Investor Events

BLACKSBURG, Va., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to develop novel ora...

1 month ago - GlobeNewsWire

Landos Biopharma Reports Second Quarter 2021 Financial Results and Provides Business Updates

Following the recent positive End-of-Phase 2 meeting with the FDA, Landos initiated global pivotal  Phase 3 clinical trial site feasibility studies of omilancor in ulcerative colitis (UC)

1 month ago - GlobeNewsWire

Landos Biopharma to Present at the Raymond James Virtual Human Health Innovation Conference

BLACKSBURG, Va., June 14, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late clinical-stage biopharmaceutical company utilizing its LANCE Advanced A.I. platform to discover and devel...

3 months ago - GlobeNewsWire

Landos Biopharma Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA for Omilancor in Mild-to-Moderate ...

The FDA clears the path to initiate the PACIFY I and II global registration studies in Mild-to-Moderate Active UC patients representing the potential for a broad product label for Omilancor The FDA clea...

3 months ago - GlobeNewsWire

Landos Biopharma to Present at the Jefferies Virtual Healthcare Conference

BLACKSBURG, Va., May 25, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late clinical-stage biopharmaceutical company utilizing its LANCE A.I. platform to discover and develop novel o...

3 months ago - GlobeNewsWire

Landos Biopharma Announces the Appointment of Tim M. Mayleben to its Board of Directors

BLACKSBURG, Va., May 19, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc (NASDAQ: LABP), a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients w...

3 months ago - GlobeNewsWire

Landos Biopharma, LianBio Ink Licensing Pact For Omilancor & NX-13 in Greater China

Landos Biopharma Inc (NASDAQ: LABP) and LianBio have announced an exclusive collaboration and license agreement for the development and commercialization of omilancor and NX-13 in Greater China (mainlan...

4 months ago - Benzinga

Landos Biopharma Reports First Quarter 2021 Financial Results and Provides Business Updates

Completed initial public offering of common stock, raising approximately $100 million in gross proceeds

4 months ago - GlobeNewsWire

Landos Biopharma to Present Two Late-Breaking Presentations on Therapeutic Potential of Omilancor and PX-69 at the 20...

BLACKSBURG, Va., April 26, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma (NASDAQ: LABP), a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with...

4 months ago - GlobeNewsWire

Landos Biopharma Announces the Appointment of Tiago Girão to its Board of Directors

BLACKSBURG, Va., April 13, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma (NASDAQ: LABP), a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with...

5 months ago - GlobeNewsWire

Landos Biopharma Stock Is Trading Higher On Initiating Early-Stage Study With Omilancor For Esophagus Inflammation

The FDA has signed off Landos Biopharma's (NASDAQ: LABP) Investigational New Drug application for omilancor (BT-11) for the treatment of Eosinophilic Esophagitis (EoE). Landos expects to initiate patien...

5 months ago - Benzinga

Landos Biopharma Announces FDA Clearance of IND Application for Omilancor for the Treatment of Eosinophilic Esophagitis

Third potential indication for omilancor (BT-11), a first-in-class candidate for the treatment of autoimmune diseases Third potential indication for omilancor (BT-11), a first-in-class candidate for the...

5 months ago - GlobeNewsWire

Landos Biopharma Announces Positive Results from a Phase 1 Study of NX-13 in Healthy Volunteers

NX-13 was well tolerated with no reported serious adverse events

6 months ago - GlobeNewsWire

Landos Biopharma to Participate in the SVB Leerink 10th Annual Global Healthcare Conference

BLACKSBURG, Va., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma (Nasdaq: LABP), a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with ...

6 months ago - GlobeNewsWire

Landos Biopharma Announces Pricing of Initial Public Offering

BLACKSBURG, Va., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune dise...

7 months ago - GlobeNewsWire

Landos Biopharma guns for a $100M IPO to boost AI autoimmune R&D work

Xontogeny’s Landos Biopharma is jumping into warm biotech IPO waters as it looks to go public with a $100 million offering.

8 months ago - FierceBiotech

Will Murky Trial Data Undercut Landos' $100 Million IPO Launch?

On January 4, the company announced slightly murky data from its first-in-patients 12-week Phase II proof-of-concept trial of BT-11 for mild to moderate ulcerative colitis.

8 months ago - BioSpace

Autoimmune biotech Landos Biopharma files for a $100 million IPO

Landos Biopharma, a Phase 2 biotech developing oral small molecule therapies for autoimmune diseases, filed on Wednesday with the SEC to raise up to $100 million in an initial public offering.

8 months ago - NASDAQ

Landos Biopharma IPO Registration Document (S-1)

Landos Biopharma, Inc. has filed to go public with an IPO on the NASDAQ.

8 months ago - SEC